Mohamad El-Zaatari1, Adam J Bass2, Reanne Bowlby3, Min Zhang4, Li-Jyun Syu5, Yitian Yang4, Helmut Grasberger4, Andrew Shreiner4, Bei Tan4, Shrinivas Bishu4, Wai K Leung6, Andrea Todisco4, Nobuhiko Kamada4, Marilia Cascalho7, Andrzej A Dlugosz5, John Y Kao8. 1. Department of Internal Medicine-Gastroenterology, University of Michigan, Ann Arbor, Michigan. Electronic address: mohamade@med.umich.edu. 2. Department of Medical Oncology and the Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts. 3. Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. 4. Department of Internal Medicine-Gastroenterology, University of Michigan, Ann Arbor, Michigan. 5. Department of Dermatology, School of Medicine, University of Michigan, Ann Arbor, Michigan. 6. Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China. 7. Department of Surgery, University of Michigan, Ann Arbor, Michigan. 8. Department of Internal Medicine-Gastroenterology, University of Michigan, Ann Arbor, Michigan. Electronic address: jykao@med.umich.edu.
Abstract
BACKGROUND & AIMS: Chronic gastrointestinal inflammation increases the risk of cancer by mechanisms that are not well understood. Indoleamine-2,3-dioxygenase 1 (IDO1) is a heme-binding enzyme that regulates the immune response via catabolization and regulation of tryptophan availability for immune cell uptake. IDO1 expression is increased during the transition from chronic inflammation to gastric metaplasia. We investigated whether IDO1 contributes to the inflammatory response that mediates loss of parietal cells leading to metaplasia. METHODS: Chronic gastric inflammation was induced in Ido1-/- and CB57BL/6 (control) mice by gavage with Helicobacter felis or overexpression of interferon gamma in gastric parietal cells. We also performed studies in Jh-/- mice, which are devoid of B cells. Gastric tissues were collected and analyzed by flow cytometry, immunostaining, and real-time quantitative polymerase chain reaction. Plasma samples were analyzed by enzyme-linked immunosorbent assay. Gastric tissues were obtained from 20 patients with gastric metaplasia and 20 patients without gastric metaplasia (controls) and analyzed by real-time quantitative polymerase chain reaction; gastric tissue arrays were analyzed by immunohistochemistry. We collected genetic information on gastric cancers from The Cancer Genome Atlas database. RESULTS: H felis gavage induced significantly lower levels of pseudopyloric metaplasia in Ido1-/- mice, which had lower frequencies of gastric B cells, than in control mice. Blood plasma from H felis-infected control mice had increased levels of autoantibodies against parietal cells, compared to uninfected control mice, but this increase was lower in Ido1-/- mice. Chronically inflamed stomachs of Ido1-/- mice had significantly lower frequencies of natural killer cells in contact with parietal cells, compared with stomachs of control mice. Jh-/- mice had lower levels of pseudopyloric metaplasia than control mice in response to H felis infection. Human gastric pre-neoplasia and carcinoma specimens had increased levels of IDO1 messenger RNA compared with control gastric tissues, and IDO1 protein colocalized with B cells. Co-clustering of IDO1 messenger RNA with B-cell markers was corroborated by The Cancer Genome Atlas database. CONCLUSIONS: IDO1 mediates gastric metaplasia by regulating the B-cell compartment. This process appears to be associated with type II hypersensitivity/autoimmunity. The role of autoimmunity in the progression of pseudopyloric metaplasia warrants further investigation.
BACKGROUND & AIMS:Chronic gastrointestinal inflammation increases the risk of cancer by mechanisms that are not well understood. Indoleamine-2,3-dioxygenase 1 (IDO1) is a heme-binding enzyme that regulates the immune response via catabolization and regulation of tryptophan availability for immune cell uptake. IDO1 expression is increased during the transition from chronic inflammation to gastric metaplasia. We investigated whether IDO1 contributes to the inflammatory response that mediates loss of parietal cells leading to metaplasia. METHODS:Chronic gastric inflammation was induced in Ido1-/- and CB57BL/6 (control) mice by gavage with Helicobacter felis or overexpression of interferon gamma in gastric parietal cells. We also performed studies in Jh-/- mice, which are devoid of B cells. Gastric tissues were collected and analyzed by flow cytometry, immunostaining, and real-time quantitative polymerase chain reaction. Plasma samples were analyzed by enzyme-linked immunosorbent assay. Gastric tissues were obtained from 20 patients with gastric metaplasia and 20 patients without gastric metaplasia (controls) and analyzed by real-time quantitative polymerase chain reaction; gastric tissue arrays were analyzed by immunohistochemistry. We collected genetic information on gastric cancers from The Cancer Genome Atlas database. RESULTS:H felis gavage induced significantly lower levels of pseudopyloric metaplasia in Ido1-/- mice, which had lower frequencies of gastric B cells, than in control mice. Blood plasma from H felis-infected control mice had increased levels of autoantibodies against parietal cells, compared to uninfected control mice, but this increase was lower in Ido1-/- mice. Chronically inflamed stomachs of Ido1-/- mice had significantly lower frequencies of natural killer cells in contact with parietal cells, compared with stomachs of control mice. Jh-/- mice had lower levels of pseudopyloric metaplasia than control mice in response to H felis infection. Human gastric pre-neoplasia and carcinoma specimens had increased levels of IDO1 messenger RNA compared with control gastric tissues, and IDO1 protein colocalized with B cells. Co-clustering of IDO1 messenger RNA with B-cell markers was corroborated by The Cancer Genome Atlas database. CONCLUSIONS:IDO1 mediates gastric metaplasia by regulating the B-cell compartment. This process appears to be associated with type II hypersensitivity/autoimmunity. The role of autoimmunity in the progression of pseudopyloric metaplasia warrants further investigation.
Authors: Kanutte Huse; Maren Bakkebø; Morten P Oksvold; Lise Forfang; Vera I Hilden; Trond Stokke; Erlend B Smeland; June H Myklebust Journal: Eur J Immunol Date: 2011-10-18 Impact factor: 5.532
Authors: Li-Jyun Syu; Mohamad El-Zaatari; Kathryn A Eaton; Zhiping Liu; Manas Tetarbe; Theresa M Keeley; Joanna Pero; Jennifer Ferris; Dawn Wilbert; Ashley Kaatz; Xinlei Zheng; Xiotan Qiao; Marina Grachtchouk; Deborah L Gumucio; Juanita L Merchant; Linda C Samuelson; Andrzej A Dlugosz Journal: Am J Pathol Date: 2012-10-01 Impact factor: 4.307
Authors: Morgan A Jones; Sean DeWolf; Vimvara Vacharathit; Michelle Yim; Stacey Spencer; Anil K Bamezai Journal: PLoS One Date: 2016-06-20 Impact factor: 3.240
Authors: Yulin Ouyang; Li Wen; Jane A Armstrong; Michael Chvanov; Diane Latawiec; Wenhao Cai; Mohammad Awais; Rajarshi Mukherjee; Wei Huang; Peter J Gough; John Bertin; Alexei V Tepikin; Robert Sutton; David N Criddle Journal: Cells Date: 2021-04-27 Impact factor: 6.600
Authors: Freek J H Sorgdrager; Petrus J W Naudé; Ido P Kema; Ellen A Nollen; Peter P De Deyn Journal: Front Immunol Date: 2019-10-30 Impact factor: 7.561